Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention.

Friedland SN, Eisenberg MJ, Shimony A.

Am J Cardiol. 2012 May 15;109(10):1397-404. doi: 10.1016/j.amjcard.2012.01.349. Epub 2012 Feb 28. Review.

PMID:
22381162
2.

A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.

Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Kim DK, Seol SH, Kim DI, Cho KI, Kim BH, Park YH, Je HG, Jeong YH, Kim WJ, Lee JY, Lee SW.

Cardiology. 2012;122(3):133-43. doi: 10.1159/000339238. Epub 2012 Jul 24. Review.

PMID:
22832424
3.

Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.

Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R.

Int J Cardiol. 2013 Sep 1;167(5):2250-8. doi: 10.1016/j.ijcard.2012.06.010. Epub 2012 Jun 22.

PMID:
22727963
4.

Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, Kim WJ, Lee JY, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Jon S, Cho YH, Lee NH, Kim JH, Park SJ.

Am J Cardiol. 2010 Jan 15;105(2):168-73. doi: 10.1016/j.amjcard.2009.08.667. Epub 2009 Dec 3.

PMID:
20102913
5.

Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.

Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, Malhotra S.

Br J Clin Pharmacol. 2009 Jul;68(1):4-13. doi: 10.1111/j.1365-2125.2009.03402.x.

6.

Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.

Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, Abbate A, Cosgrave J, Laudito A, Trevi GP, Sheiban I.

Am Heart J. 2008 Jun;155(6):1081-9. doi: 10.1016/j.ahj.2007.12.024. Epub 2008 Feb 19.

PMID:
18513523
7.

Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.

Chen Y, Zhang Y, Tang Y, Huang X, Xie Y.

Curr Med Res Opin. 2014 Jan;30(1):37-49. doi: 10.1185/03007995.2013.850067. Epub 2013 Oct 18. Review.

PMID:
24083626
8.

Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.

Tamhane U, Meier P, Chetcuti S, Chen KY, Rha SW, Grossman MP, Gurm H.

EuroIntervention. 2009 Aug;5(3):384-93. Review.

PMID:
19736165
9.
10.

Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.

Jennings DL, Kalus JS.

J Clin Pharmacol. 2010 Apr;50(4):415-21. doi: 10.1177/0091270009338940. Epub 2010 Jan 16. Review.

PMID:
20081227
11.

Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.

Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, Shu Q, Tang X.

Am Heart J. 2009 Apr;157(4):733-9. doi: 10.1016/j.ahj.2009.01.006. Epub 2009 Mar 17.

PMID:
19332203
12.

Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.

Chen J, Meng H, Xu L, Liu J, Kong D, Chen P, Gong X, Bai J, Zou F, Yang Z, Li C, Eikelboom JW.

J Thromb Thrombolysis. 2015 Jan;39(1):23-34. doi: 10.1007/s11239-014-1090-5. Review.

PMID:
24869717
13.

Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.

Geng DF, Liu M, Jin DM, Wu W, Deng J, Wang JF.

Cardiology. 2012;122(3):148-57. doi: 10.1159/000338812. Epub 2012 Jul 24. Review.

PMID:
22832561
14.

Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ; Korea Acute Myocardial Infarction Registry Investigators.

Circulation. 2009 Jun 30;119(25):3207-14. doi: 10.1161/CIRCULATIONAHA.108.822791. Epub 2009 Jun 15.

15.

The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.

Wang P, Zhou S, Zhou R, Liu G, Tang P, He J, Ma C, He Y, Yang J.

Clin Cardiol. 2012 Oct;35(10):598-604. doi: 10.1002/clc.22001. Epub 2012 May 14. Review.

16.

Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy after drug-eluting stent implantation in coronary arteries: A meta-analysis of randomized controlled trials.

Zou Y, Hu C, Ye W, Fan L, Xu L, Zhang A.

Thromb Res. 2015 Nov;136(5):870-7. doi: 10.1016/j.thromres.2015.08.018. Epub 2015 Aug 29.

PMID:
26342401
17.

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.

Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S.

Can J Cardiol. 2011 Sep-Oct;27(5):548-54. doi: 10.1016/j.cjca.2011.03.017. Epub 2011 Aug 25.

PMID:
21871775
18.

Use of cilostazol in percutaneous coronary interventions.

Rogers KC, Faircloth JM, Finks SW.

Ann Pharmacother. 2012 Jun;46(6):839-50. doi: 10.1345/aph.1Q765. Epub 2012 Jun 5. Review.

PMID:
22669796
19.

Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.

Zhang Z, Foster JK, Kolm P, Jurkovitz CT, Parker KM, Murrah NV, Anderson GT, Douglas JS Jr, Weintraub WS.

Am Heart J. 2006 Oct;152(4):770-6.

PMID:
16996857
20.

Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis.

Zhang Y, Tang HQ, Li J, Fu ZX.

Chin Med J (Engl). 2013;126(9):1750-4.

PMID:
23652062

Supplemental Content

Support Center